Prognia
Drug Database
🇪🇺EU · EMAWithdrawnConditional Approval

Beqvez (previously Durveqtix)(fidanacogene elaparvovec)

Hemophilia B

Marketing Authorisation Holder: Pfizer Europe MA EEIG

EMA Authorisation: 24/07/2024

INN: fidanacogene elaparvovec

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Beqvez (previously Durveqtix) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.